# DESCRIPTION

## FIELD OF THE INVENTION

- relate to bifunctional compounds for neurological diseases

## BACKGROUND OF THE INVENTION

- describe Alzheimer's disease
- introduce PROTAC strategy

## SUMMARY OF THE INVENTION

- introduce PROTAC-based compounds for tau protein degradation
- describe tau binding moieties
- describe E3 ubiquitin ligase binding moieties
- provide formula for compounds
- describe tau protein binding moiety T
- provide formula for T-I
- provide formula for T-II
- provide formula for T-III and T-IV
- describe E3 ubiquitin ligase binding moiety E
- provide examples of compounds
- describe uses of compounds

## DEFINITIONS

### Chemical Definitions

- define chemical terms
- introduce stereochemistry concepts
- describe isotopic variations
- define aliphatic and heteroaliphatic groups
- define alkyl and haloalkyl groups
- define heteroalkyl
- define alkenyl
- define heteroalkenyl
- define alkynyl
- define heteroalkynyl
- define carbocyclyl
- define cycloalkyl
- specify heteroalkyl embodiments
- specify alkenyl embodiments
- specify heteroalkenyl embodiments
- specify alkynyl embodiments
- specify heteroalkynyl embodiments
- specify carbocyclyl embodiments
- specify cycloalkyl embodiments
- specify substituents
- define heterocyclyl
- describe heterocyclyl groups
- provide examples of heterocyclyl groups
- define aryl
- describe aryl groups
- provide examples of aryl groups
- define heteroaryl
- describe heteroaryl groups
- provide examples of heteroaryl groups
- define aralkyl
- define heteroaralkyl
- define unsaturated bond
- define unsaturated and saturated
- describe affixing suffixes
- describe optional substitution
- provide examples of substituents
- define Raa
- define Rbb
- define Rcc
- define Rdd
- define Ree
- define Rff
- define Rgg
- define halo
- define hydroxyl
- define amino, sulfonyl, sulfinyl, and acyl
- define carbonyl group
- define silyl group
- define oxo and thiooxo groups
- define nitrogen atom substituents
- introduce nitrogen protecting groups
- list amide nitrogen protecting groups
- list carbamate and sulfonamide nitrogen protecting groups
- define nitrogen protecting groups
- list examples of nitrogen protecting groups
- define oxygen protecting groups
- list examples of oxygen protecting groups
- define sulfur protecting groups
- list examples of sulfur protecting groups
- define counterions
- list examples of counterions
- define leaving groups
- list examples of leaving groups
- define non-hydrogen group
- provide general information about substituents

### Other Definitions

- define salt
- describe pharmaceutically acceptable salt
- introduce solvate
- explain hydrate
- define tautomers
- describe isomers
- introduce stereoisomers
- define diastereomers
- define enantiomers
- describe polymorph
- introduce prodrugs
- define composition and formulation
- describe subject
- introduce biological sample
- define tissue
- describe administer
- introduce treatment
- define condition, disease, and disorder
- describe effective amount
- introduce therapeutically effective amount and prophylactically effective amount

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- introduce bifunctional compounds

### Compounds

- define compounds interacting with tau protein and E3 ubiquitin ligase
- describe compound of Formula I
- define tau protein binding moiety T
- describe Formula T-I for T
- specify embodiments of Formula T-I
- define compounds
- specify R3 embodiments
- specify R1, R2, and R4 embodiments
- define formula T-I-a
- specify R3 embodiments in formula T-I-a
- define formula T-I-b
- specify R3 embodiments in formula T-I-b
- define additional formulas for T
- define compounds
- specify formula T-II
- provide embodiments of formula T-II
- specify formula T-II-a
- provide embodiments of formula T-II-a
- specify formula T-II-b
- provide embodiments of formula T-II-b
- specify formulas T-III and T-IV
- provide embodiments of formulas T-III and T-IV
- define compounds
- specify R20
- specify G
- specify R22
- specify T
- specify tau binding moiety
- define group L
- specify L structure
- provide L embodiments
- define compounds
- specify embodiments of L
- define RA
- specify embodiments of RA
- define E
- describe Cereblon
- specify embodiments of E
- describe Formula E-I
- specify embodiments of Formula E-I
- describe Formula E-II and E-III
- specify embodiments of Formula E-II and E-III
- define compounds
- specify embodiments of formula E-II
- specify embodiments of formula E-II-a
- specify embodiments of formula E-II-b
- specify embodiments of formula E-II-c
- specify embodiments of formula E-II-d
- specify embodiments of formula E-II-e
- specify embodiments of formula E-II-f
- specify embodiments of formula E-II-g
- specify embodiments of formula E-II-g-1 and E-II-g-2
- define compounds
- specify E formula
- specify Y options
- specify E-III-a formula
- specify E-III-a options
- specify E-III-b formula
- define compounds
- describe embodiments of formula E-III-c
- describe embodiments of formula E-III-d
- describe embodiments of formula E-III-e
- describe VHL protein structure
- describe E as modulator, binder, inhibitor, or ligand of VHL
- describe E as peptide backbone structure
- describe E3 ligase binding moiety binding affinity
- describe E3 ligase binding moiety selectivity
- describe additional embodiments of E

### Further Embodiments of Formula I

- define compound of Formula I-a
- specify E3 ubiquitin ligase binding moiety
- describe R9 substituents
- detail R3 substituents
- specify A substituents
- describe R2, R7, and R8 substituents
- specify n and q values
- provide optional carbon replacements
- repeat embodiments with varying L, M, X, R9, and R3
- repeat embodiments with varying A and R2, R7, and R8
- provide final embodiment with specific R3 and A substituents
- define compound of Formula I-a
- define compound of Formula I-b
- define compound of Formula I-b-1
- define compound of Formula I-b-2
- define compound of Formula I-b-3
- define compound of Formula I-c
- define formula I-c
- specify embodiments of formula I-c
- specify embodiments of formula I-c
- specify embodiments of formula I-c
- specify embodiments of formula I-c
- define formula I-d
- specify embodiments of formula I-d
- specify embodiments of formula I-d
- define formula I-e
- define formula I
- specify Rx and Ry
- specify n and q
- define formula I-e
- specify R20, G, and R22
- provide multiple embodiments of formula I-e
- define formula I-f
- specify E, G, R23, R24, Rx, and Ry
- provide multiple embodiments of formula I-f
- define formula I-g to I-k
- specify T and q
- provide multiple embodiments of formula I
- specify radionuclide incorporation
- specify binding affinity for tau protein
- specify selectivity for tau protein
- specify promotion of tau protein degradation

### Pharmaceutical Compositions, Kits, and Administration

- define pharmaceutical compositions
- describe compound of Formula I
- specify effective amounts
- describe subjects
- specify tau protein degradation
- describe pharmaceutical compositions for treating neurological disorders
- describe pharmaceutical compositions for treating neurodegenerative diseases
- describe pharmaceutical compositions for treating tauopathies
- describe administration with additional pharmaceutical agents
- describe pharmaceutical agents
- describe solid and liquid pharmaceutical compositions
- describe formulation with pharmaceutically acceptable excipients
- describe administration routes
- describe dosage levels
- describe preparation methods
- describe pharmaceutical composition packaging
- describe excipients
- list antioxidants
- list chelating agents
- list antimicrobial preservatives
- list antifungal preservatives
- list alcohol preservatives
- list acidic preservatives
- list other preservatives
- list buffering agents
- list lubricating agents
- list natural oils
- list synthetic oils
- describe liquid dosage forms
- describe injectable preparations
- describe solid dosage forms
- describe topical formulations
- describe kits

### Methods of Treatment

- motivate tau protein degradation
- describe methods of treating neurological disorders
- provide methods of treating neurodegenerative diseases
- provide methods of treating tauopathies
- describe methods of promoting tau protein degradation
- describe methods of binding E3 ubiquitin ligase
- provide methods of administering compounds
- describe methods of treating Alzheimer's disease
- provide methods of preventing neurological disorders
- provide methods of preventing neurodegenerative diseases
- provide methods of preventing tauopathies

### Diagnostic Methods

- motivate in vivo imaging of aberrant tau protein
- describe radiolabeled compounds as imaging agents
- describe fluorescence imaging techniques
- describe nuclear imaging techniques
- provide methods for detecting neurological disorders
- provide methods for detecting pathological aggregation of tau protein
- provide methods for diagnosing neurological disorders

## EXAMPLES

- provide synthetic examples

### Preparation of Synthetic Intermediates

- prepare intermediate C
- prepare intermediate D
- prepare intermediate E
- prepare intermediate F

### N-(6-02-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide (1; QC-01-178))

- prepare compound 1

### (2S,4R)-1-[(2S)-3,3-Dimethyl-2-(3-{2-[2-(3-{5H-pyrido[4,3-b]indol-7-yl}propanamido)ethoxy]ethoxy}propanamido)butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-earboxamide (8; FMF-05-129-1)

- prepare intermediate M
- prepare compound 8

### 2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}-N-{2-[2-(2-{2-[(5-{5H-pyrido[4,3-b]indol-7-yl}pyridin-2-yl)oxy]acetamido}ethoxy)ethoxy]ethyl}acetamide (15; FMF-05-183-1)

- synthesize compound R
- synthesize compound S
- synthesize compound 15

### N-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethyl]-2-[(5-{5H-pyrido [4,3-b]indol-7-yl}pyridirt-2-yl)oxy]acetamide (19; FMF-05-167-1)

- synthesize compound S
- synthesize compound 19
- characterize compound 19

### Tau Degradation Assays

- introduce tau degradation assays
- describe experimental design
- detail cell preparation and lysis
- explain Western blot procedure
- present results for compounds 1-12
- evaluate effect of T807 on tau levels
- reevaluate compounds 2-5 for tau degradation
- assess effect on E3 ubiquitin ligases
- evaluate compounds 2-5 in non-mutant control neurons
- determine time and dose-dependency effect

### In Vivo Assay

- describe pharmacokinetic study design
- detail sample collection and processing
- present results for compound 3

## Equivalents And Scope

- define claim language
- establish scope of invention
- discuss equivalents and modifications

